In Vivo depletion of lymphotoxin-alpha expressing lymphocytes inhibits xenogeneic graft-versus-host-disease

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Chiang, Eugene Y ^a   Kolumam, Ganesh ^a   McCutcheon, Krista M ^a   Young, Judy ^a   Lin, Zhonghua ^a   Balazs, Mercedesz ^a   Grogan, Jane L ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LYMPHOTOXIN; LYMPHOTOXIN ALPHA ANTIBODY; MLTA 3698A; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; B LYMPHOCYTE ACTIVATION; CELL ACTIVITY; CONTROLLED STUDY; FEMALE; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; MALE; MEMBRANE BINDING; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; SURVIVAL TIME; T LYMPHOCYTE ACTIVATION; TARGET CELL; UPREGULATION; XENOGRAFT; ALLOTRANSPLANTATION; ANIMAL; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNOLOGY; LYMPHOCYTE; MOUSE MUTANT; SURFACE PLASMON RESONANCE;

MUS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GRAFT VS HOST DISEASE; HUMANS; LYMPHOCYTES; LYMPHOTOXIN-ALPHA; MICE; MICE, SCID; SURFACE PLASMON RESONANCE; TRANSPLANTATION, HOMOLOGOUS;

EID: 84858031529     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0033106     Document Type: Article

References (32)

1. Messina C, Faraci M, de Fazio V, Dini G, Calo MP, et al. (2008) Prevention and treatment of acute GvHD. Bone Marrow Transplant 41: S65-70.
2. Paczesny S, Hanauer D, Reddy P, (2010) New perspectives on the biology of acute GVHD. Bone Marrow Transplant 45: 1-11.
3. Busca A, (2011) The use of monoclonal antibodies for the treatment of graft-versus-host disease following allogeneic stem cell transplant. Expert Opin Biol Ther 11: 687-697.
4. Tyndall A, Dazzi F, (2008) Chronic GVHD as an autoimmune disease. Best Pract Res Clin Haematol 21: 281-289.
5. Alousi AM, Uberti J, Ratanatharathorn V, (2010) The role of B cell depleting therapy in graft versus host disease after allogeneic hematopoietic cell transplant. Leuk Lymphoma 51: 376-389.
6. Patriarca F, Skert C, Sperotto A, Zaja F, Falleti E, et al. (2006) The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery. Exp Hematol 34: 389-396.
7. Sarantopoulos S, Stevenson KE, Kim HT, Cutler CS, Bhuiya NS, et al. (2009) Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood 113: 3865-3874.
8. Ho VT, Cutler C, (2008) Current and novel therapies in acute GVHD. Best Pract Res Clin Haematol 21: 223-237.
9. Ware CF, (2005) Network communications: lymphotoxins, LIGHT and TNF. Annu Rev Immunol 23: 787-819.
10. Chiang EY, Kolumam GA, Yu X, Francesco M, Ivelja S, et al. (2009) Targeted depletion of lymphotoxin-alpha-expressing TH1 and TH17 cells inhibits autoimmune disease. Nat Med 15: 766-773.
11. Gramaglia I, Mauri DN, Miner KT, Ware CF, Croft M, (1999) Lymphotoxin alphabeta is expressed on recently activated naive and TH1-like CD4 cells but is down-regulated by IL-4 during TH2 differentiation. J Immunol 162: 1333-1338.
12. Ware CF, Crowe PD, Grayson MH, Androlewicz MJ, Browning JL, (1992) Expression of surface lymphotoxin and tumor necrosis factor on activated T, B, and natural killer cells. J Immunol 149: 3881-3888.
13. Browning JL, Sizing ID, Lawton P, Bourdon PR, Rennert PD, et al. (1997) Characterization of lymphotoxin-alpha beta complexes on the surface of mouse lymphocytes. J Immunol 59: 3288-3298.
14. Katschke KJ Jr, Helmy KY, Steffek M, Xi H, Yin J, et al. (2007) A novel inhibitor of the alternative pathway of complement reverses inflammation and bone destruction in experimental arthritis. J Exp Med 204: 1319-1325.
15. Castellana NE, McCutcheon L, Pham VC, Harden K, Nguyen A, et al. (2011) Resurrection of a clinicall antibody: template proteogenomic de novo proteomic sequencing and reverse engineering of an anti-lymphotoxin-alpha antibody. Proteomics 11: 395-405.
16. Cupedo T, Crellin NK, Papazian N, Rombouts EJ, Weijer K, et al. (2009) Human fetal lymphoid tissue-inducer cells are interleukin 17-producing precursors to RORC+ CD127+ natural killer-like cells. Nat Immunol 10.
17. Sandhu JS, Gorczynski R, Shpitz B, Gallinger S, Nguyen HP, et al. (1995) A human model of xenogeneic graft-versus-host disease in SCID mice engrafted with human peripheral blood lymphocytes. Transplantaion 60: 179-184.
18. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, et al. (1997) Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57: 4593-4599.
19. Chuntharapai A, Lai J, Huang X, Gibbs V, Kim KJ, et al. (2001) Characterization and humanization of a monoclonal antibody that neutralizes human leukocyte interferon: a candidate therapeutic for IDDM and SLE. Cytokine 15: 250-260.
20. Adams CW, Allison DE, Flagella K, Presta L, Clarke J, et al. (2006) Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother 55: 717-727.
21. Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, et al. (2001) High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 276: 6591-6604.
22. Iori AP, Torelli GF, De Propris MS, Milano F, Pupella S, et al. (2008) B-cell concentration in the apheretic product predicts acute graft-versus-host disease and treatment-related mortality of allogeneic peripheral blood stem cell transplantation. Transplantaion 85: 386-390.
23. Carpenter PA, Appelbaum FR, Corey L, Deeg HJ, Doney K, et al. (2002) A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood 99: 2712-2719.
24. Pinana JL, Valcarcel D, Martino R, Moreno ME, Sureda A, et al. (2006) Encouraging results with inolimomab (anti-IL-2 receptor as treatment for refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 12: 1135-1141.
25. Kanda J, Lopez RD, Rizzieri DA, (2011) Alemtuzumab for the prevention and treatment of graft-versus-host disease. Int J Hematol.
26. Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, et al. (2003) CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 9: 1144-1150.
27. Chamian F, Lin S-L, Lee E, Kikuchi T, Gilleaudeau P, et al. (2007) Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis. J Transl Med 5: 27.
28. Lo DJ, Weaver TA, Stempora L, Mehta AK, Ford ML, et al. (2011) Selective targeting of human alloresponsive CD8+ effector memory T cells based on CD2 expression. Am J Transplant 11: 22-33.
29. Deeg HJ, Blazar BR, Bolwell BJ, Long GD, Schuening F, et al. (2001) Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL. Blood 98: 2052-2058.
30. MacMillan ML, Couriel D, Weisdorf DJ, Schwab G, Havrilla N, et al. (2007) A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease. Blood 109: 2657-2662.
31. Shpitz B, Chambers CA, Singhal AB, Hozumi N, Fernandes BJ, et al. (1994) High level functional engraftment of severe combined immunodeficiency mice with human peripheral blood lymphocytes following pretreatment with radiation and anti-asial GM1. J Immunol Methods 169: 1-15.
32. Wilson J, Cullup H, Lourie R, Sheng Y, Palkova A, et al. (2009) Antibody to the dendritic cell surface activation antigen CD83 prevents acute graft-versus-host disease. J Exp Med 206: 387-398.